Boston, Massachsetts (PRWEB)
May 26, 2017
Leading CEOs from biotech, pharmaceutical, and healthcare investing communities will gather at Boston CEO 2017 on May 30th and 31st at The Four Seasons Hotel Boston.
The Boston CEO Conference is an off-the-record networking forum for leading executives in the life sciences, offering exclusive access to key decision makers who influence deal making and investment. Attendees gain insight from presentations and panels featuring CEOs from several of the world’s leading biopharmaceutical companies. Healthcare and finance investors also attend this world-class meeting.
FDA’s Richard Moscicki will give a keynote speech. John Maraganore (Alnylam), Robert Coughlin (MassBio), David Meek (IPSEN), and Mike Ehlers (Biogen) will speak in Fireside Chats moderated by Christoph Westphal (Longwood Fund).
The conference will commence with a remembrance for the late Henri Termeer, “Remembering a Biotech Legend: Henri Termeer” with Christoph Westphal, Rob Perez, Deborah Dunsire, Geoffrey McDonough, and Richard Moscicki.
John Maraganore, CEO of Alnylam, says, “The Boston CEO conference is an invaluable opportunity for CEOs to gather in a casual and off-the-record atmosphere and discuss the most pressing issue in the biotech space and beyond. I look forward to these conferences and fully support their mission to continue to grow Boston’s thriving biopharma community.”
Panel topics include a CEO roundtable, healthcare market outlook, diversity: moving from sound bite to implementation, ensuring transparency and drug value, cell & gene therapy, building a biotech, evolving biotech boards, Boston-Bound biotech and pharma, achieving organizational turnarounds, and many more.
The 2017 Boston CEO Lifetime Achievement Award will be presented by last year’s winner, Robert Couhglin (MassBio) and 2015 winner, John…